Dinaciclib

Dinaciclib (SCH-727965) is an experimental drug that inhibits cyclin-dependent kinases (CDKs). It is being evaluated in clinical trials for various cancer indications. Dinaciclib is being developed by Merck & Co. It was granted orphan drug status by the FDA in 2011.
Wikipedia contributors, "Dinaciclib", Wikipedia, revision 1386284733, retrieved 20 November 2026, source, CC BY-SA 4.0.